The precocity and efficacy of the vaccines developed so far against COVID-19 has been the most significant and saving advance against the pandemic. The development of vaccines has not prevented, during the whole period of the pandemic, the constant search for therapeutic medicines, both among existing drugs with different indications and in the development of new drugs. The Scientific Committee of the COVID-19 of the Illustrious College of Physicians of Madrid wanted to offer an early, simplified and critical approach to these new drugs, to new developments in immunotherapy and to what has been learned from the immune response modulators already known and which have proven effective against the virus, in order to help understand the current situation.
Keywords: AZD7442; Adalimumab; Anakinra; Azithromycin; BRII-196; BRII-198; Banlanivimab; Baricitinib; COVID-19; Canakinumab; Casirivimab; Certolizumab; Ciganilmab; Colchicine; Dexamethasone; Etanercept; Etesevimab; Evusheld; Favipiravir; Fluvoxamine; Golimumab; Hydroxychloroquine; Imdevinab; Infliximab; Itolizumab; Ivermectin; Lemilumab; Lopinavir/Ritonavir; Metformin; Molnupiravir; PF-07321332; Paxlovid; Ravulizumab; Remdesivir; Ruxolitinib; SARS-CoV-2; Sarilumab; Sotrovimab; Tixagevimab; Tocilizumab; Tofacitinib; Vitamin D; convalescent plasma; treatment.
©The Author 2021. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).